Transamerica Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Transamerica Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$505K	Buy	1,016 +75	+8%	+$33.2K	0.04%	288
2026 Q1	$420K	Sell	941 -6,643	-88%	-$3.1M	0.04%	302
2025 Q4	$3.44M	Sell	7,584 -131	-2%	-$56.5K	0.29%	96
2025 Q3	$3.02M	Buy	7,715 +84	+1%	+$35.1K	0.25%	88
2025 Q2	$3.4M	Sell	7,631 -220	-3%	-$101K	0.32%	78
2025 Q1	$3.81M	Sell	7,851 -101	-1%	-$47.1K	0.39%	66
2024 Q4	$3.2M	Sell	7,952 -222	-3%	-$103K	0.32%	82
2024 Q3	$3.8M	Buy	8,174 +7,713	+1,673%	+$3.71M	0.37%	76
2024 Q2	$216K	Hold	461	–	–	0.02%	195
2024 Q1	$193K	Sell	461 -3,004	-87%	-$1.27M	0.02%	218
2023 Q4	$1.41M	Sell	3,465 -1,120	-24%	-$414K	0.19%	86
2023 Q3	$1.59M	Sell	4,585 -1,065	-19%	-$372K	0.22%	82
2023 Q2	$1.99M	Buy	5,650 +167	+3%	+$56.3K	0.26%	66
2023 Q1	$1.73M	Sell	5,483 -156	-3%	-$46.8K	0.23%	76
2022 Q4	$1.63M	Hold	5,639	–	–	0.23%	83
2022 Q3	$1.63M	Buy	5,639 +253	+5%	+$72.8K	0.24%	70
2022 Q2	$1.52M	Buy	+5,386	New	+$1.44M	0.21%	67
2021 Q3	–	Sell	-5	Closed	-$1K	–	200
2021 Q2	$1K	Buy	+5	New	+$1.05K	0.02%	194
2016 Q2	–	Sell	-259	Closed	-$21K	–	702
2016 Q1	$21K	Sell	259 -191	-42%	-$17.3K	﹤0.01%	480
2015 Q4	$57K	Hold	450	–	–	﹤0.01%	393
2015 Q3	$47K	Sell	450 -410	-48%	-$52.7K	﹤0.01%	395
2015 Q2	$107K	Buy	860 +425	+98%	+$53.6K	0.01%	378
2015 Q1	$52K	Buy	+435	New	+$52.1K	﹤0.01%	434

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Transamerica Financial Advisors's VRTX Position: Q2 2026 in Review

Transamerica Financial Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 8% in Q2 2026, buying an estimated $33.2K and bringing the position to 1,016 shares worth $505K. The position accounts for 0.04% of the portfolio, ranked #288.

Transamerica Financial Advisors first reported a position in VRTX in Q1 2015 and has held it in 23 quarters since. The position peaked at $3.81M in Q1 2025. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Transamerica Financial Advisors held 1,016 shares of Vertex Pharmaceuticals worth $505K as of Q2 2026.
Transamerica Financial Advisors bought 75 Vertex Pharmaceuticals shares in Q2 2026, an estimated $33.2K.
Vertex Pharmaceuticals made up 0.04% of Transamerica Financial Advisors's portfolio in Q2 2026, its #288 holding.
Transamerica Financial Advisors first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 23 quarters since.
Transamerica Financial Advisors's Vertex Pharmaceuticals position peaked at $3.81M in Q1 2025.
1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.